MedTrace Logo

XTX501 in Patients With Metastatic Non-Small Cell Lung Cancer and Advanced Solid Tumors

NCT07688577 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2026-07-07

No results posted yet for this study

Summary

This is a first-in-human, multicenter, Phase 1/2, open-label study designed to evaluate the safety and tolerability of XTX501 as monotherapy in participants with metastatic non-small cell lung cancer (NSCLC) and select advanced solid tumors.

Conditions

  • Metastatic NSCLC - Non-Small Cell Lung Cancer
  • Advanced Solid Tumor

Interventions

DRUG

XTX501

XTX501 monotherapy

Sponsors & Collaborators

  • Xilio Development, Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-31
Primary Completion
2029-11-30
Completion
2029-11-30
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07688577 on ClinicalTrials.gov